CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bergenbio ASA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bergenbio ASA
Mollendalsbakken 9
Phone: +47 55961159p:+47 55961159 BERGEN, 5009  Norway Ticker: BGBIOBGBIO
Business Summary
Bergenbio ASA is a Norway-based clinical-stage biopharmaceutical company focused on developing drugs for aggressive diseases including cancer and severe respiratory infections. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The Company's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board AndersTullgren 61 1/6/2022 1/6/2022
Chief Executive Officer MartinOlin 53 9/8/2021 9/8/2021
Chief Financial Officer RuneSkeie 48 9/8/2021 3/5/2018
9 additional Officers and Directors records available in full report.

Business Names
Business Name
0RU5
7BG
BGBIO
BGBIOO
BRRGF

General Information
Number of Employees: 15 (As of 9/30/2024)
Outstanding Shares: 39,087,116 (As of 9/30/2024)
Stock Exchange: OSL


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024